摘要
目的比较阿立哌唑与舒必利治疗慢性精神分裂症患者的临床疗效及安全性。方法将78例慢性精神分裂症患者随机分成研究组和对照组各39例,分别予以阿立哌唑及舒必利治疗8周,采用阳性症状及阴性量表(PAN SS)评定临床疗效,副反应量表TESS评定副反应。结果治疗8周后阿立哌唑和舒必利显效率分别为76.9%和74.4%,二者疗效相当,差异无显著性,不良反应阿立哌唑46.2%,舒必利66.7%,二者比较差异有显著性(P<0.05)。结论阿立哌唑治疗慢性精神分裂症有疗效好,不良反应少,安全性高的特点。
Objective To compare the efficacy and safety between aripirazole and sulpiride in the treatment of chronic schizophrenia. Methods 78 patients with chronic schizophrenia were raidomly divided into study group（n= 39） and control group （n= 39） ,treated with aripiprazole and sulpiride respectively for 8 weeks. The postitive and negative syndomly scale （PANSS） and treament emergemt symptom scale （TESS） were used to assess the therapeutic efficacy and side effect respictively. Results Aripiprazole was as effective as sulpiride for the treatment of chronic schizophrenia （P〉0. 05）. The marked improement rate of the former was 76.9% and the later was 74.4%. The incidence rate of adverse effect was 46.2% in Aripiprazole group and that was 66.7% in Sulpiride group. Significant differences were observed between them （P〈0. 05）. Conclusion Aripiprazole is an effective and sale drug in the treatment of chronic schizophrenia . It＇s side effects were fewer.
出处
《中国健康心理学杂志》
2009年第5期518-520,共3页
China Journal of Health Psychology
